2006 BEHOLD TRIAL A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B multicenter, double-blind, double-dummy, randomized controlled trial M Objective: To compare the efficacy and safety of 48 weeks of therapy with entecavir with 48 weeks of therapy with lamivudine in patients with HBeAg-positive chronic hepatitis B who had not previously received a […]